AGI-101H vaccine in the Treatment of Patients with Advanced Melanoma Long Term Safety and Survival Follow up - ASAS

Study Objectives

  • To determine the long term safety profile of AGI-101H administered subcutaneous for extended use of its effect on long term survival.


  • Protocol Number: AGI – 101H/01-2008
  • EudraCT Number: 2008-007607-80
  • Execution time: February 2009 – 2016

Sponsor: AGIRx Ltd. South Essex, UK